MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 74 filers reported holding MIRUM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,500,834 | +12.7% | 617,115 | -7.7% | 0.07% | +21.1% |
Q2 2023 | $17,303,796 | -18.9% | 668,875 | -24.7% | 0.06% | -21.9% |
Q1 2023 | $21,343,067 | +15.6% | 888,554 | -6.1% | 0.07% | +9.0% |
Q4 2022 | $18,457,491 | -48.8% | 946,538 | -44.9% | 0.07% | -5.6% |
Q3 2022 | $36,062,013 | +4.5% | 1,716,422 | -3.2% | 0.07% | +10.9% |
Q2 2022 | $34,498,325 | -20.4% | 1,772,798 | -9.9% | 0.06% | +3.2% |
Q1 2022 | $43,327,915 | +173.7% | 1,967,658 | +98.2% | 0.06% | +55.0% |
Q4 2021 | $15,831,000 | -6.7% | 992,555 | +16.5% | 0.04% | -16.7% |
Q3 2021 | $16,975,000 | -25.8% | 852,172 | -35.6% | 0.05% | +45.5% |
Q2 2021 | $22,878,000 | +102.9% | 1,323,184 | +132.6% | 0.03% | -2.9% |
Q1 2021 | $11,277,000 | +111.4% | 568,982 | +86.3% | 0.03% | +100.0% |
Q4 2020 | $5,334,000 | +21.4% | 305,486 | +34.0% | 0.02% | +6.2% |
Q3 2020 | $4,393,000 | -32.4% | 227,990 | -31.8% | 0.02% | +23.1% |
Q2 2020 | $6,502,000 | +48.1% | 334,080 | +6.6% | 0.01% | +18.2% |
Q1 2020 | $4,390,000 | – | 313,502 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |